Tolero Pharmaceuticals Inc., a late-stage pharmaceutical company developing treatments for serious hematological diseases, has entered into an exclusive license to use Eutropicsc PraediCare Dx platform in the clinical development of alvocidib. Preliminary studies have suggested that PraediCareDx can be used to identify acute myeloid leukemia (AML) patients with a high likelihood of responding to alvocidib. Tolero is currently initiating a randomized Phase II study in previously treated AML pa...